The drug 3,4-methylenedioxyethamphetamine ([MDE] also known as "Eve") is a less toxic analog of 3,4-mtthylenedioxymethamphetamine (also known as "Ecstasy") with similar psychotropic effects in humans.
every 20 minutes until 5:00 P.M. Administration of MDE was followed by statistically significant long-lasting increases of serum cortisol, PRL, systolic blood pressure, and heart rate, and by a trend toward blunting of GH secretion. The neuroendocrine and cardiovascular effects of MDE are comparable to those of other phenethyl amines with the exception of the effect on GH secretion. lNeuropsychopharmacology 8: 187-193, 1993J out distortion of sensory perception and thought and without marked stimulation Tolbert 1986, 1990; Peroutka et al. 1988) . Pharmacologic studies on the structure-activity relationships of MDMA and related compounds supported the view that MDMA and MDE might constitute a new psychoactive sub stance class, which was named the "entactogens" (Nichols 1986; Nichols and Oberlender 1990) .
The reasons for the public controversy about MDMA are its growing popularity and illegal abuse dur ing the past years (Seymour 1986; Beck and Morgan 1986; Beck 1990) , its reported medical usefulness as an adjunct in insight-oriented psychotherapy (Grinspoon and Bakalar 1986; Greer and Tolbert 1990) , and its pos sible neurotoxicity in humans (Price et al. 1989; Grob et al. 1990 ). In experimental animals, MDA and MDMA were shown to exert neurotoxic effects on central serotonergic neurons resulting in degeneration of axon terminals (Ricaurte et al. 1985 (Ricaurte et al. , 1988 Battaglia et al. 1988b Battaglia et al. , 1990 Insel et al. 1989; Gibb et al. 1990; Schmidt et al. 1990 ). It is not yet clear whether this fmding has a relevance for humans (Peroutka et al. 1987; Price et al. 1989; Grob et al. 1990 ), but it played an important role for the assignment of MDMA to Schedule I status by the Drug Enforcement Agency in 1985. After the 0893-133X/93/$6.00 scheduling of MDMA its N-ethyl analog, MDE ("Eve"), became more popular and served as an MDMA substi tute for recreational use (Beck 1990 ). The action of MDE is supposed to be more subtle and shorter (3 to 4 hours), but otherwise very similar to the action of MDMA.
Studies of animal behavior underlined the similarity be tween MDE and MDMA (Boja and Schechter 1987) .
Neurochemical studies showed that MDE is far less toxic than MDA and MDMA (Schmidt 1987; Ricaurte et al. 1987; Stone et al. 1987; Gibb et al. 1990 ).
Both MDMA and MDE show high affinities at ser otonin (5-HT) uptake sites, and lower affinities at nor epinephrine and dopamine (DA) uptake sites of cen tral neurons (Battaglia et al. 1988a) . They are taken up into the neurons and cause release and reuptake in hibition of the endogenous transmitters (Johnson et al. 1986 (Johnson et al. ,1988 Steele et al. 1987; Schmidt 1987) . In ad dition, the substances have low affinities at 5-HT2-, 5-HT1-, and D2-binding sites, but those seem to be less important for the drugs' action (Lyon et al. 1986; Battaglia et al. 1988a ).
In our literature review, we found only anecdotal reports about the psychotropic effects and no human experimental data on neurobiologic effects of the drugs.
The aim of our investigation was to study the phar macokinetics and metabolism, as well as the psycho logic and neurobiologic effects (endocrine, polysomno graphic, cardiovascular) of MDE in healthy volunteers, and to attempt a characterization of the substance. In this paper, we present the neuroendocrine and cardio vascular studies.
Studies of the neuroendocrine effects of centrally acting drugs may contribute to the pharmacologic char acterization of these substances. Numerous studies demonstrate that 5-HT and 5-HT agonists stimulate hypothalamic neurons that regulate adrenocorticotropic hormone and corticosterone secretion from the pitu itary and adrenocortex, respectively (Fuller 1981) . The secretion of prolactin (PRL) from the anterior pituitary is regulated by inhibitory tuberoinfundibular dopamin ergic neurons and by an indirect stimulatory serotoner gic mechanism (Gudelsky 1981; Van de Kar et al. 1985a ).
The secretion of growth hormone (GH) is stimulated by enhanced catecholaminergic and serotonergic trans mission (Brown et al. 1978; Matussek 1988; Meltzer and Nash 1988) . Both MDMA and MDE provoke release and reuptake inhibition of 5-HT in the central nervous sys tem (CNS), and to a lesser extent also of norepineph rine and dopamine (Johnson et al. 1986 (Johnson et al. ,1988 Steele et al. 1987 and a questionnaire for vegetative lability). The exclu sion criteria were any signifIcant physical illness requir ing therapy, any mental illness, and alcohol or sub stance abuse at present or in the past, as defIned by DSM-IIJ criteria. Mental illness in fIrst degree relatives was also an exclusion criterion. No volunteer had pre vi ous experience with MDE. One subject reported one experience with MDMA 2 years before. Another sub ject reported sporadic experience with cannabis about 10 to 15 years before, and one experience with MDMA 1.5 years before. A third subject reported spora dic experience with cannabis and one experience with D-lysergic acid (LSD) about 7 to 10 years before. All psychometric measurements were within normal range, except for the FPI dimension "openness," in which a higher than average mean score was obtained.
The complete psychometric data are reported in a sep arate paper (HermIe et al., 1993) .
Substances
The MDE used in this study was synthesized at the In stitute of Pharmaceutics, University of Tiibingen and was obtained in the form of 70 mg capsules. Placebo capsules were obtained from the same institute. The volunteers received 140 mg of MDE, a dose commonly taken for recreational use (Greer and Strassman 1985; Beck and Morgan 1986; Seymour 1986; Peroutka 1990 ).
Experimental Design
Subjects arrived at the hospital at 12:00 A.M. They re ceived a standardized calorie-and electrolyte-balanced diet for lunch, and then entered the laboratory. Sub jects had to stay awake and supine with head and up per trunk elevated on a bed in a single sound-isolated room during the trial while they were observed by a video camera with a monitor located in the neighbor ing laboratory unit. until the time of assay. The subjects were examined for heart rate and blood pressure every 20 minutes from 2:00p.M. to 5:00 P.M. After the end of the trial subjects remained in the hospital for another 2 to 3 hours and were monitored clinically and cardiovascularly. If neces sary, transportation home was arranged for them, and astaff member stayed with them until the next day. The second trial (placebo/MOE) was performed 1 to 4 weeks after the frrst trial.
The investigation was part of a pilot study on psy chologic and neurobiologic effects of MDE on normal control subjects and was performed in accordance with the requirements of the Declaration of Helsinki. The study was approved by the local ethics committee of the University of Freiburg. In addition to the above de scribed neuroendocrine and cardiovascular tests the volunteers participated in a series of psychometric tests, which were performed before ingestion of the drug, and at 2, 5, and 24 hours after ingestion of the drug, as well as 7 days after the trial. Pharmacokinetics and metabo lism of the drug were investigated in the blood and urine samples of the subjects at the Institute of Pharmaceu tics, University of Tiibingen. Evaluation of the phar maceutical/toxicological data is currently in progress.
The psychometric data are reported in a separate pa per (Hermle et al., 1993) .
Hormone Determinations
Serum concentrations of cortisol, PRL, and GH were measured using commercial kits. The coefficients of variation were as follows. For cor tisol: 4.4 to 7.9 (within assay) and 5.2 to 9.7 (between assay); for PRL 2.7 to 4.8 (within assay) and 3.9 to 7.3 (between assay); and for GH 3.7 to 5.7 (within assay) and 9.7 to 11.4 (between assay).
Statistical Analysis
Mean values and standard deviation (SO) were calcu lated for all data. The time course of hormone concen tration and cardiovascular data were analyzed by mul tivariate analysis of variance (MANOY A) with repeated measurements. Further analysis was performed with two-tailed Student's t-tests, followed by the Bonferroni procedure. Statistically signrncant p values were con sidered to be those less than 0.05.
RESULTS

Neuroendocrine Data
Following placebo administration, cortisol and PRL lev els were stable, except for a slight decrease in plasma cortisol during the registration period, which was in terpreted as relief from stress. SignifIcant long-lasting increases in serum cortisol and PRL were produced by MDE (MANOYA, P = .001 and .0197, respectively). Fol lowing placebo administration, four of the eight volun teers showed one or two secretion peaks for GH during the registration period. Following MOE administration the GH level remained stable in all volunteers during the entire registration period. However, the resulting diff erence in GH levels after MDE and placebo, indicat ing a blunting of GH secretion after MOE administra tion, was not statistically signifIcant (MANOY A, P = .0870). The neuroendocrine data are shown in Figure   1 (t-test, Bonferroni procedure).
Cardiovascular Data
Blood pressure and heart rate remained stable after placebo administration. Long-lasting increases in sys tolic blood pressure and heart rate were produced by MDE (MANOY A, P = .006 and .001, respectively). The increase in diastolic blood pressure after MOE adminis tration was not statistically signihcant (MANOY A, P =
.053). The cardiovascular data are shown in Figure 2 (t-test, Bonferroni procedure).
DISCUSSION
Oral administration of 140 mg of MOE to eight healthy male volunteers was followed by signifIcant increases The effects of 140 mg MDE or placebo on serum levels of cortisol (A), prolactin (B), and growth hormone (HGH) (C) in eight healthy male volunteers (X and SD; t-test; Bonferroni procedure: .p < .05; "p < .01; ".p < .001). Time o = MDE/placebo administration.
in plasma cortisol and PRL concentrations and a trend toward decrease of GH secretion.
A probable explanation for the effects of MOE on plasma cortisol and PRL levels might be an indirect serotonergic mechanism. This would be in line with ex perimental data from animal studies. In vitro studies on rat brain slices showed that MOMA and MOE evoke release and inhibit reuptake of endogenous 5-HT and catecholamines, the preferential effects being on the serotonergic, and the weakest effects on the OA sys tems (Johnson et al. 1986; Steele et al. 1987; Battaglia et al. 1988a ). Serotonin and norepinephrine are known The effects of 140 mg MDE or placebo on systolic blood pressure (A), diastolic blood pressure (B), and heart rate (C) in eight healthy male volunteers (x and SD; t-test; Bonferroni procedure: .p < .05;
to stimulate the secretion of cortisol and PRL (Laakmann 1990; Matussek 1988; Meltzer and Nash 1988) . and Nash and Meltzer (1990) showed that MOMA stimulates the secretion of cortisol and PRL in the rat. In those studies the effect of MOMA on cortisol secretion was clearly shown to be mediated via serotonergic mechanisms, as it was blocked or blunted by 5-HT2 antagonists or pretreatment with fluoxetine or p-chlorophenylalanine. The mechanism mediating PRL secretion could not be entirely clarmed; however, the authors of that case hypothesized that a serotoner gic mechanism was responsible, because the effect was blunted after pretreatment with p-ch1orophenylalanine. They came to the conclusion that MDMA requires en dogenous 5-HT to stimulate the secretion of PRL and corticosterone . In studies with other amphetamine derivatives similar effects on plasma cor tisol and PRL were also demonstrated (Mc Elroy et al. 1984; Van de Kar et al. 1985a, b) . Finally, the phenethyl amine psychedelic mescaline and the indole psychedelic N,N-dimethyltryptamine (N,N-DMT), which act via 5-HT-dependent mechanisms, were also shown to in crease plasma PRL (Demisch and Neubauer 1979; Melt zer et al. 1978 Melt zer et al. , 1981 .
In contrast, the observed trend toward a decrease of serum GH following MDE administration is difficult tointerpret. To our knowledge, there are no previous experimental data on the effect of MDMA or MDE on GH secretion. However, a substance enhancing release ofendogenous 5-HT and catecholamines and acting as a direct 5-HT agonist would be expected to cause aug mentation of GH secretion (Brown et a1. 1978 ; Laak mann 199 0; Meltzer and Nash 1988) . The increase of GH plasma levels was demonstrated in numerous studies following administration of amphetamines (Besser et al. 1969; Parkes et al. 1977 ) and the hallucino genic substances mescalin, N,N-DMT, and LSD (De mischand Neubauer 1979; Meltzer et a1. 1981) . The ob served trend toward blunting of GH secretion following MDE administration in our study might indeed support the hypothesis of a novel psychoactive substance class (Nichols 1986 ). However, this effect was not statistically signifIcant . Further studies are needed to better assess this potentially interesting fmding.
The cardiovascular effects of MDE with long-lasting signifIcant rises in blood pressure and heart rate un derli ne its sympathomimetic properties. Similar sym pathomimetic effects were reported in a human pilot study (Downing 1986 ) after ingestion of MDMA and were frequently observed with the use of amphetamine and derivatives (Turek et al. 1974; Angrist et a1. 1987) . As in the study of Downing (1986) , the volunteers had noparticu1ar discomfort or awareness of the altered car diovascular parameters, and mostly felt calm and re laxed (unpublished data of the psychometric tests). The cardiovascular effects of MDE might be mediated via indirect catecholaminergic mechanisms (release and re uptake inhibition of norepinephrine).
In conclusion, the neuroendocrine and cardiovas cular effects of MDE in normal control subjects were similar to the effects of other amphetamines and chem icall y related hallucinogens, as previously reported in the literature. The trend toward blunting of GH secre tion is perhaps an exception in this respect and is a potentially interesting fInding, but it was not statisti call y signihcant. Evaluation of the data derived from our studies on the subjective and polysomnographic eff ects of MDE in healthy volunteers also stresses the Endocrine Effects of MDE 191 similarities of MDE to stimulant amphetamines: in these studies a marked overall stimulation with increased vi gility was shown to be the most robust effect of MDE. Also in those studies we found some potentially in teresting trends (nonsuppression of slow-wave-sleep, simultaneous appearance of increased psychomotor drive, subjective feelings of relaxation, diminished anxi ety, and depressed mood), that might indicate unique effect patterns of MDE, but those fIndings also did not reach statistical signifIcance (unpublished data). Fur ther investigations are needed in order to assess the neurobiologic and subjective effects of MDE and related substances and thus contribute to the pharmacologic characterization of the "entactogens."
